(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 103.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Bridgebio Pharma's revenue in 2025 is $127,415,000.On average, 6 Wall Street analysts forecast BBIO's revenue for 2025 to be $48,434,014,535, with the lowest BBIO revenue forecast at $18,665,274,776, and the highest BBIO revenue forecast at $74,945,920,184. On average, 6 Wall Street analysts forecast BBIO's revenue for 2026 to be $104,816,056,247, with the lowest BBIO revenue forecast at $80,809,436,818, and the highest BBIO revenue forecast at $129,080,913,456.
In 2027, BBIO is forecast to generate $213,106,929,670 in revenue, with the lowest revenue forecast at $149,151,305,560 and the highest revenue forecast at $259,965,693,752.